Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $182.79 Average Price Target from Brokerages

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) have received an average recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $184.00.

JAZZ has been the topic of several research reports. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and upped their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Robert W. Baird dropped their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Finally, Royal Bank of Canada dropped their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th.

Jazz Pharmaceuticals Stock Down 0.6%

NASDAQ:JAZZ traded down $0.65 during trading hours on Monday, hitting $108.80. 637,538 shares of the stock traded hands, compared to its average volume of 837,962. The firm has a 50 day moving average price of $108.37 and a 200 day moving average price of $121.04. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The firm has a market cap of $6.71 billion, a price-to-earnings ratio of 15.32, a PEG ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm's quarterly revenue was down .5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.68 earnings per share. Equities research analysts anticipate that Jazz Pharmaceuticals will post 16.96 earnings per share for the current year.

Insider Activity

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at $966,323.72. This trade represents a 13.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $107.90, for a total value of $53,950.00. Following the transaction, the chief executive officer now owns 438,473 shares in the company, valued at approximately $47,311,236.70. This trade represents a 0.11% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,623 shares of company stock valued at $1,826,916. Insiders own 4.20% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of JAZZ. Barclays PLC grew its position in shares of Jazz Pharmaceuticals by 19.1% in the third quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock valued at $4,369,000 after purchasing an additional 6,289 shares during the last quarter. Blue Trust Inc. grew its holdings in Jazz Pharmaceuticals by 83.7% in the 4th quarter. Blue Trust Inc. now owns 1,868 shares of the specialty pharmaceutical company's stock valued at $230,000 after buying an additional 851 shares during the last quarter. Institute for Wealth Management LLC. acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at approximately $260,000. Caprock Group LLC acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at approximately $206,000. Finally, Trust Point Inc. acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at approximately $213,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.